The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU

HIV Infections Clinical Trial

Official title:

The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00000654
• Other study ID #: ACTG 122 FIAU
• Secondary ID: R90-001-01, 02,
• Status: Completed
• Phase: Phase 2
• First received: November 2, 1999
• Last updated: December 17, 2012
• Est. completion date: February 1993

Study information

• Verified date: December 2012
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

To determine the tolerance of HIV-infected patients to TID oral doses of FIAU syrup at 4 different dose levels. To determine the peak and trough blood levels of FIAU and its metabolites during two weeks of oral dosing with FIAU.

The pyrimidine nucleoside analog FIAC and its primary deaminated uracil metabolite FIAU are highly and specifically active compounds in vitro against several herpes group viruses, particularly herpes simplex virus (HSV) types 1 and 2, varicella zoster (VZV), and cytomegalovirus (CMV), as well as hepatitis B virus (HBV). Since FIAU is the primary metabolite of FIAC and the administration of FIAU simplifies the metabolism of FIAC, it is anticipated from clinical studies of FIAC that FIAU will be tolerated at least as well as FIAC. A single-dose, pharmacokinetic (blood level) study showed that FIAC, when taken orally, is readily absorbed into the bloodstream, and most of it is converted to FIAU. Daily oral doses are expected to provide concentrations of FIAU exceeding the in vitro minimum inhibitory concentration for nearly all the herpes group viruses.

Description:

The pyrimidine nucleoside analog FIAC and its primary deaminated uracil metabolite FIAU are highly and specifically active compounds in vitro against several herpes group viruses, particularly herpes simplex virus (HSV) types 1 and 2, varicella zoster (VZV), and cytomegalovirus (CMV), as well as hepatitis B virus (HBV). Since FIAU is the primary metabolite of FIAC and the administration of FIAU simplifies the metabolism of FIAC, it is anticipated from clinical studies of FIAC that FIAU will be tolerated at least as well as FIAC. A single-dose, pharmacokinetic (blood level) study showed that FIAC, when taken orally, is readily absorbed into the bloodstream, and most of it is converted to FIAU. Daily oral doses are expected to provide concentrations of FIAU exceeding the in vitro minimum inhibitory concentration for nearly all the herpes group viruses.

HIV-infected patients with Karnofsky scores at least 80 (with or without documented recurrent herpes group infections) are successively entered into consecutively studied, escalating dose cohorts. There are a total of 4 dose cohorts of FIAU and each patient takes the required amount of FIAU syrup every 8 hours, 1 hour prior to or 3 hours after meals, for a total of 14 days. Entry of new patients at the next higher dose is based on results of tolerance and safety data for prior cohort when all 10 have received 14 days of therapy and at least 7 have met all of the tolerance criteria. Although not formally randomized due to the sequential nature of the study and serious medical condition of the patients, every attempt to avoid bias in assigning a patient to a dose is made. Patients are entered starting with the first dose cohort. Upon meeting the enrollment and tolerance criteria for dose escalation, up to 5 patients with a history of chronic HBV infection and surface antigen positive at their screening visit are added to the end of each dose cohort. Plasma samples are taken to determine peak and trough levels of FIAU at Days 1, 3, 7, and 14 or at last visit. Patients with ongoing active infections are followed by culture (HSV, VZV and CMV) or test (HBV) at Days 1, 3, 7, and 14. Antiemetic therapy with Reglan, Compazine, and Trilafon is given concomitantly at the discretion of the investigator and tolerance determined with antiemetic therapy ongoing. Patients are advised to avoid heavy exercise within 24 hours of any laboratory tests.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 78
• Est. completion date: February 1993
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 13 Years to 65 Years

Eligibility

Inclusion Criteria

Concurrent Medication:

Allowed:

• Pentamidine aerosol for prophylaxis of recurrent Pneumocystis carinii pneumonia (PCP) in patients currently receiving such treatment.

• Zidovudine (AZT).

Prior Medication:

Allowed:

• Zidovudine (AZT) but only if patient has been taking the drug for > 6 weeks at a dose = or < 600 mg/day, and had < 10 percent decrease in hematocrit, neutrophils, and platelets in the last 30 days.

Patients must:

• Have a diagnosis of HIV infection by ELISA or Western blot. Be able to participate as an outpatient.

• Be ambulatory.

• Have Grade 0 or 1 AIDS Clinical Trial Group toxicity grades for specified laboratory tests.

• Be competent to sign informed consent.

• Be able to cooperate with the treatment plan and evaluation schedule.

NOTE:

• The screening tests must be initiated and completed within 4 weeks prior to the first dose of FIAU, except for diagnostic herpes simplex virus (HSV), varicella zoster (VZV), or cytomegalovirus (CMV) cultures which may have been done previously.

• Concomitant diseases allowed:

• Stable mucocutaneous disease.

• Superficial or uncomplicated infections such as thrush.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

• HIV wasting syndrome (involuntary weight loss > 10 percent of baseline body weight and/or chronic diarrhea or weakness and documented fever for at least 30 days).

• Clinical or x-ray evidence of bronchitis, pneumonitis, pulmonary edema, effusion, or suspected active tuberculosis.

• Any unstable medical condition including serious infections or cardiovascular, oncologic, renal, or hepatic condition.

• Primary or initial infection with herpes simplex (HSV), varicella zoster (VZV), or hepatitis B (HBV).

• Cytomegalovirus (CMV) end organ disease.

• Kaposi's sarcoma requiring chemotherapy.

• Systemic fungal infection requiring amphotericin therapy.

• Diagnosis of idiopathic thrombocytopenic purpura (persistent platelet counts < 100000 platelets/mm3 for = or > 3 months).

Patients with the following are excluded:

• HIV wasting syndrome.

• Clinical or x-ray evidence of bronchitis, pneumonitis, pulmonary edema, effusion, or suspected active tuberculosis.

• Any unstable medical condition including serious cardiovascular, infections, oncologic, renal, or hepatic condition.

• Primary or initial infection with herpes simplex (HSV), varicella zoster (VZV), or hepatitis B (HBV).

• Cytomegalovirus (CMV) end organ disease.

Prior Medication:

Excluded within 4 weeks of study entry:

• Ganciclovir (DHPG).

• Foscarnet.

• Interferon.

• Other drug with putative antiviral activity (except zidovudine (AZT)).

• Any immunostimulating drug not specifically allowed.

Excluded within 1 week of study entry:

• Acyclovir.

Study Design

Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Communicable Diseases
• Hepatitis B
• Herpes Simplex
• HIV Infections
• Infection
• Virus Diseases

Intervention

Drug:
• Fialuridine

Locations

Country	Name	City	State
United States	Natl Institute of Health	Bethesda	Maryland
United States	Univ of Alabama at Birmingham	Birmingham	Alabama
United States	Univ of California / San Diego Treatment Ctr	San Diego	California
United States	Univ of Washington / Madison Clinic	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Oclassen Pharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (1)

Tartaglione T, Hooton TM, Jones T, Smiles K, Corey L. Actg 122: phase II tolerance study of oral FIAU in HIV-infected persons. Int Conf AIDS. 1991 Jun 16-21;7(2):254 (abstract no WB2290)